Kornimate/medical-research-clean huggingface dataset:
targeted interdisciplinary model for evaluation and treatment of neuropscyhiatric symptoms

Conditions: Dementia

Summary: almost all people who suffer from dementia experience neuropsychiatric symptoms (nps) in the course of the disease. time (targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms) is a multicomponent intervention based on the theoretical framework of cognitive behavioral therapy (cbt). the time trial is designed to assess the effects of time on nps in nursing homes patients with dementia and the implementation process at staff and organization level.

time (targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms) is a multicomponent intervention based on the theoretical framework of cognitive behavioral therapy (cbt).the time trial includes a three months cluster randomized trial in 36 nursing homes with 164 participants with dementia and a high level of agitation. each nursing home defines a cluster and will be randomized to receive either the intervention with time or a brief two hours education-only intervention about dementia and nps for the control group. time consists of a manual based multicomponent program which includes a rigorous assessment, the treatment, and the evaluation of neuropsychiatrc symptoms (nps). the staff, physicians and nursing home managers receive a one-day education. three nurses from each unit will receive further education including practical and theoretical training for three hours. measurements at patient level are taken at baseline prior to randomization and at eight and twelve weeks. the primary outcome measure is agitation. mixed methods will be used to follow, measure and explore the implementation process and the effect at individual staff level and at organization level.

Eligibility criteria:
inclusion criteria: 1. clinical dementia rating scale (cdr) 1 or higher. 2. moderate to high grade of agitation defined by the npi-nh agitation item as equal to or above six points. 3. planned long-term stay in the nursing home, and a minimum of two weeks stay in the nursing home before inclusion. exclusion criteria: 1.terminal phase (life expectancy less than 4-6 weeks)

Keywords: behavioral symptoms psychological symptoms dementia neuropsychiatric symptoms
a study of xeloda (capecitabine) in combination with avastin + short course chemotherapy in patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of xeloda and avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with metastatic colorectal cancer. patients were randomized to receive 2-weekly cycles of treatment with either: 1) xeloda, avastin and oxaliplatin; or 2) xeloda, avastin and irinotecan. after 9 cycles, patients continued to receive maintenance treatment with xeloda + avastin. the anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, ≥18 years of age * histologically confirmed adenocarcinoma of colon or rectum, with unresectable metastatic or locally advanced disease * ≥1 measurable target lesion * ambulatory, with an eastern cooperative oncology group (ecog) performance status of ≤1 exclusion criteria: * prior systemic therapy for advanced or metastatic disease * history of another malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of the cervix * clinically significant cardiovascular disease * current or recent use of full dose oral warfarin or full dose parenteral anticoagulants or thrombolytic agents * chronic daily treatment with \>325 mg/day aspirin
achilles tendon repair with bioinductive implant

Conditions: Tendinopathy

Summary: to evaluate bioinduction of new tissue and tendon healing after implantation of the rotation medical bioinductive implant used as adjunct to surgical repair in the treatment of insertional achilles tendonitis.

this is a prospective, non-randomized, single-arm study conducted under a common protocol designed to evaluate long-term outcomes following open treatment and implantation of the rotation medical bioinductive implant to treat insertional achilles tendinopathy. up to 20 subjects will be enrolled and treated with the rotation medical bioinductive implant. enrollment is anticipated to take up to 12 months and all subjects will be followed for two years after surgery. therefore, the overall study duration is estimated to be 36 months.

Eligibility criteria:
inclusion criteria: 1. at least 21 years of age 2. insertional achilles tendonitis requiring surgery that has failed conservative management, which consist of: a. shoe modification b. nonsteroidal anti-inflammatory drugs c. physical therapy with/without modalities 3. chronic achilles tendon pain lasting longer than 3 months 4. mri or x-ray of the ankle within 60 days prior to the study procedure 5. willing to comply with the prescribed post-operative rehabilitation program 6. willing to be available for each protocol-required follow-up examination 7. able to understand the informed consent process, including regulatory requirements such as hipaa authorization, and document informed consent prior to completion of any study-related procedures 8. ability to read, understand, and complete subject-reported outcomes in english exclusion criteria: 1. achilles tendon rupture 2. previous achilles tendon surgery on the index ankle 3. genetic collagen disease 4. history of auto-immune or immunodeficiency disorders 5. history of chronic inflammatory disorders 6. oral steroid use in last 2 months or injectable steroid use in last 4 weeks 7. history of heavy smoking (\> 1 pack per day) within last 6 months 8. hypersensitivity to bovine-derived materials 9. hypersensitivity to polylactic acid (pla) and polyetheretherketone (peek) materials 10. metal implants, fillings, shrapnel, and/or screws 11. females of child-bearing potential who are pregnant or plan to become pregnant during the course of the study 12. currently involved in any injury litigation or worker's compensation claims relating to the index ankle 13. enrolled, or plans to enroll, in another clinical trial during this study that would affect the outcomes of this study 14. history of non-compliance with medical treatment, physical therapy/rehabilitation, or clinical study participation 15. history of cognitive or mental health status that interferes with study participation

Keywords: insertional achilles
canagliflozin with gemcitabine in pancreatic carcinoma

Conditions: Pancreatic Cancer

Summary: gemcitabine-based chemotherapy or combination with folfirinox is the leading treatment of pancreatic cancer. however, the overall response rate of pancreatic cancer to gemcitabine is less than 20%. resistance to gemcitabine is the most important reason. there is an urgent need to develop new combination therapies to improve the efficiency of chemotherapy, avoid toxicity limitations, and improve the overall prognosis of pancreatic cancer. at present, it has been found that canagliflozin can reduce the expression level of pd-l1 in pancreatic cancer and restore the vitality of cd8+ t cells. canagliflozin combined with gemcitabine may improve the efficiency of chemotherapy.


Eligibility criteria:
1. inclusion criteria: # age ≥18 years old; #metastatic or unresectable pancreatic cancer is confirmed through histology or cytology; # estimated survival time \> 3 months; # without any chemotherapy treatment or more than one month from the end of the last chemotherapy course; #ecog physical status score 0-2; 2. exclusion criteria: # patients who had allergic reaction to therapeutic drugs; # patients with other types of cancer; # patients with severe diseases of heart, liver, kidney, etc.; (4) gastrointestinal dysfunction or unable to oral medication. 3. shedding/eliminating criteria: exiting in the midway; lost to follow-up during the follow-up period; treatment was not continued according to the treatment protocol.
prospective exploratory study to evaluate the safety and efficacy of telbivudine in the fifth year of treatment in chinese patients with compensated chronic hepatitis b

Conditions: Hepatitis B, Chronic

Summary: this study will explore efficacy and safety of telbivudine in the fifth year of treatment.


Eligibility criteria:
inclusion criteria * patient completed omnibus study and will be available to immediately rollover into this study without discontinuation of study drug. * patient was not discontinued from the previous omnibus study. * male or female, adult patients with chb (hbeag positive or hbeag negative). * patient is willing and able to provide written informed consent to participate in the study. * hbv dna pcr undetectable in recent 12 months. exclusion criteria * pregnant or breastfeeding, or has plan of pregnant during study period. * patient is co-infected with hepatitis c virus (hcv), hepatitis d virus (hdv), r hiv at screening visit. * patient needs any anti-hbv treatment combination (add-on therapy) or switch to other anti hbv treatment from telbivudine at investigator's discretion. * patient has any laboratory value abnormality that physicians think he/she may not be suitable to continue the telbivudine treatment. * patient has any clinically significant concurrent severe or unstable disease conditions that physicians think he/she may have any additional risk or not be suitable to participate the study. * patient has evidence of renal insufficiency defined as patient requiring dialysis or having an estimated creatinine clearance below 50ml/min, as estimated by the cockcroft-gault formula. * patient is currently abusing alcohol or illicit drugs. * patient is enrolled or plans to enroll in another clinical trial of an investigational agent while participating in this study. * all other treatments for hepatitis b, including commercially available treatments indicated for conditions other than chronic hepatitis b that are being investigated to treat or may have activity against hbv (e.g., ribavirin, famciclovir, ganciclovir, etc.) * prolonged use of systemic acyclovir or famciclovir defined as episodic treatment with these agents for periods exceeding 10 days every 3 months, or chronic suppressive therapy. * systemic immunomodulators of any type. * systemic corticosteroids ( topical and inhaled corticosteroids are permitted). * herbal medications known to cause hepatotoxicity (e.g., st. john's wart, kava, jin bu huan, yuzhitang, germander, chaparral, shark cartilage, mistletoe, slim 10, lipokinetix, etc.). * patient has any of the following laboratory values: * hemoglobin \< 9 g/dl for menor \<8 g/dl for women. * total wbc \<1,500/mm3 * absolute neutrophil count (anc)\<1,000/mm3 * platelet count \<30,000/mm3 * serum albumin \<2.5g/dl * total bilirubin ≥4×uln * serum creatinine \>1.5×uln

Keywords: hepatitis b, chronic telbivudine polymerase chain reaction
searching for predictive biomarkers of efficacy in small cell lung cancer patients treated with chemotherapy-immunotherapy combination using imaging mass cytometry (hype)

Conditions: Small Cell Lung Carcinoma

Summary: the goal of this retrospective study is to identify predictive biomarkers of efficacy in tumor samples of small cell lung cancer patients treated with chemotherapy-immunotherapy combination using imaging mass cytometry. the main question it aims to answer is: is there any feature in the tumour microenvironment that can discriminate responders from non responders before treatment? participants will provide consent for the collection of their clinical data and the study of their tumor samples

small cell lung cancer patients treated with first-line atezolizumab plus platinum-etoposide regimen with available formalin fixed paraffin embedded (ffpe) biopsies at baseline will be identified from brest university hospital medical records and their samples will be retrieved from brest university hospital pathology laboratory for imaging mass cytometry analyses. clinical data will be collected for each patient, including progression-free survival (defined as the time between treatment start and date of progression according to investigator, or death from any cause) and overall survival (defined as the time between treatment start and date of death from any cause). for imaging mass cytometry analyses, a panel of 39 metal-tagged antibodies will be used to characterize the cell composition of lung tumors at baseline (inflammatory, tumor and stromal cells). statistical analyses will be performed to correlate the composition of the tumor microenvironment at baseline and the survival data.

Eligibility criteria:
inclusion criteria: * patients with extensive or metastatic small cell lung cancer * patients who started a first line treatment with atezolizumab plus carboplatin and etoposide in routine practice before february 2021 * patients with available tumor sample before treatment start * no objection from living patients exclusion criteria: * patients who started first line treatment with atezolizumab plus carboplatin and etoposide in routine practice after february 2021 * patients having received immunotherapy in a clinical trial * patients with auto-immune disorder * patients under legal protection (guardianship, curatorship) * patients refusing to participate to the study

Keywords: biomarker immunotherapy
a new enzymatic assay for rapid diagnosing of central nervous system enteroviral infection

Conditions: Viral Meningitis

Summary: a new enzymatic assay was developed by nmd diagnostics for rapid diagnosis of enteroviral cns infection. this study will compare this assay to rt-pcr, by testing human csf samples taken from children at the er who are undergoing a spinal tap due to suspicion of meningitis.

mnd's new enzymatic assay is based on the detection of a specific viral enzyme through the detection of its enzymatic reaction. the detection of a specific enzymatic reaction is indicative to the presence of the specific virus in a biological specimen. this study will compare this diagnostic assay to rt-pcr for diagnosis of enteroviral infection in cerebrospinal fluid. csf samples will be taken from children undergoing a spinal tap at the pediatric er due to a suspicion of meningitis. a total of 100 samples will be collected, from children 0-16 years old who's parents agreed on participation in the study. a comparison of the enzymatic assay to rt-pcr as well as calibration and validation of the new assay will be done with the harvested samples, for a rapid and accurate identification of enterovirus in human cerebrospinal fluid.

Eligibility criteria:
inclusion criteria: * any child undergoing a spinal tap * parents agreed on participation exclusion criteria: * refusal to participate in the study

Keywords: enterovirus aseptic meningitis real time pcr diagnostics
snoring in pregnancy and adverse maternal and fetal outcomes

Conditions: Sleep Apnea Syndromes

Summary: the purpose of the study is to determine the prevalence of sleep-disordered breathing in pregnant women during the third trimester of pregnancy and to investigate whether this is associated with high blood pressure in the mother and/or growth retardation in the baby.


Eligibility criteria:
inclusion criteria: * women attending obstetric clinics at university of michigan hospitals. * willing and able to provide informed consent. * aged 18 years or older exclusion criteria: * aged under 18 years

Keywords: sleep-disordered breathing snoring pregnancy fetal growth retardation pre-eclampsia
effect of nortriptyline on abdominal pain/discomfort and quality of life in patients with nonulcer dyspepsia

Conditions: Non Ulcer Dyspepsia

Summary: the purpose of this study is to determine if use of nortriptyline will improve symptoms and quality of life in patients who have nonulcer dyspepsia.

nonulcer dyspepsia is a common complaint in clinical practice and its management should be based on the best evidence. many clinical trials of nonulcer dyspepsia suffer from important weaknesses in trial design. this makes it difficult to determine whether truly efficacious therapies exist for this disorder. once a diagnosis of nonulcer dyspepsia is confirmed by normal endoscopy, a trial of therapy is commonly prescribed. however, the benefits of all therapies in this condition have been questioned. small studies have suggested benefit in use of antidepressants such as nortriptyline and even though the data is insufficient, antidepressants such as nortriptyline are widely used in clinical practice largely due to lack of proven, reliable therapies for nonulcer dyspepsia. our hypothesis is that nortriptyline will improve symptoms of nonulcer dyspepsia and improve quality of life.

Eligibility criteria:
inclusion criteria: * men and women * ages 18-65 * meet rome iii criteria for functional dyspepsia * endoscopy within 1 year exclusion criteria: * allergic reaction or history of adverse events with nortriptyline or tricyclic antidepressants * organic cause found on physical examination * organic cause found on lab work: complete blood count, comprehensive metabolic panel, thyroid stimulating hormone, tissue transglutaminase immunoglobulin a * predominantly gastroesophageal reflux symptoms * current helicobacter pylori infection * history of peptic ulcer disease * non steroidal antiinflammatory use use \> 2x/wk * pregnant or planning pregnancy * history of major depression * abdominal surgery in the last year

Keywords: nonulcer dyspepsia functional dyspepsia antidepressant use in dyspepsia nortriptyline tricyclic antidepressants
the depth of right bronchial blocker placement in taiwanese in video-assisted thoracoscopic surgery(vats)

Conditions: Lung Tumor; Pneumothorax

Summary: a retrospective study to demonstrate the optimal depth of right side bronchial blocker for complete right lung separation. data were collected from all patients who completed right side vats with right side bb from jan 2010 through nov 2010.

after general anesthesia, an 8.0 mm internal-diameter single-lumen endotracheal tube was inserted orally. an independent coopdech bronchial blocker, which has a formed-curvature near the catheter tip, was directly inserted through the single-lumen endotracheal tube into right main bronchus. chest inspection, auscultation, fiberoptic bronchoscopy confirmation, if necessary, by visualizing the blocker cuff located at right main bronchus just below the carina was performed firstly. after placing patients in left decubitus position, the position of bb was reconfirmed by auscultation firstly; then complete collapse of the right upper lobe was adjust, if necessary and reconfirmed on the video of thoracoscopy by both surgeon and anesthesiologists. the depth of bb and the need of fiberoptic bronchoscope were recorded. all the patients were extubated in operation room after completion of operation with optimal analgesia. data collected included; age, sex, body height and weight and the depth of right-sided bb from incisor was then recorded.

Eligibility criteria:
inclusion criteria: * patients receiving right side vats( video-assisted thoracoscopic surgery) with right side bronchial blocker exclusion criteria: * patients receiving thoracic surgery with double lumen tubes

Keywords: bronchial blocker vats
effect of nerve block under ultrasound on postoperative prognosis in children

Conditions: Quality of Recovery

Summary: the goal of this study was to compare the incidence of pain and recovery agitation after single-port laparoscopic inguinal hernia repair in children. the main questions it aims to answer are: * reduction of postoperative pain by rectus sheath block compared with local anesthesia infiltration and control group * a comparison between rectus sheath block and local anesthesia infiltration and control group on the reduction of agitation during postoperative recovery if there is a comparison group: the researchers will compare the ultrasound-guided rectus sheath group with the local anesthesia infiltration group and the control group to look at postoperative pain indicators and the incidence of waking agitation.

postoperative emergence delirium is a common phenomenon in clinical practice, with an incidence rate of up to 20% to 80%. it has long been a concern and research topic in the medical community. in recent years, with the continuous improvement and updating of anesthesia technology, research on pediatric emergence delirium has become more and more in-depth. the goal of this study was to compare the incidence of pain and recovery agitation after single-port laparoscopic inguinal hernia repair in children. the main questions it aims to answer are: * reduction of postoperative pain by rectus sheath block compared with local anesthesia infiltration and control group * a comparison between rectus sheath block and local anesthesia infiltration and control group on the reduction of agitation during postoperative recovery if there is a comparison group: the researchers will compare the ultrasound-guided rectus sheath group with the local anesthesia infiltration group and the control group to look at postoperative pain indicators and the incidence of waking agitation.

Eligibility criteria:
inclusion criteria: * age: 5\~12 years old male and female single hole inguinal hernia repair surgery should be performed parents volunteered to participate in the study and signed an informed consent exclusion criteria: * preexisting neuropathy coagulopathy local skin infection hepatic, renal, or cardiorespiratory failure local anesthetic allergy

Keywords: nerve block hernia in the groin paed score flacc score
fatigue, psychological comorbidity and quality of life among patients with chronic pancreatitis in china.

Conditions: Chronic Pancreatitis

Summary: this study will investigate the status of fatigue, psychological comorbidity and quality of life among patients with chronic pancreatitis in china and analyze their influencing factors.

chronic pancreatitis (cp) is an inflammatory disease characterized by pancreatic fibrosis. available studies suggested that the incidence of cp in china was about 13.5 per 100,000 people. patients with cp often have symptoms of pancreatic endocrine and exocrine insufficiency such as elevated blood sugar, weight loss, muscle loss, combined with complications such as pancreatic duct stones, pancreatic duct stenosis, pancreatic pseudocysts, and have a higher risk of pancreatic cancer, which seriously affects the quality of life of patients. psychological comorbidities represented by anxiety and depression were thought to be widespread in cp patients, with available epidemiological studies indicating that the prevalence of anxiety and depression in cp patients in the united states was 36.8% and 46.8%, respectively. in addition, fatigue, as a subjective perception of decreased ability to perform physical and/or intellectual tasks, has also been founded among cp patients. however, to date, there is a lack of epidemiological studies on fatigue, anxiety, depression and quality of life in chinese patients with cp. this study will investigate the epidemiological status of fatigue, anxiety, depression, and quality of life in chinese patients with cp and analyze the factors influencing them.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic pancreatitis exclusion criteria: * illiterate * having communication difficulties * unable to complete the questionnaires * having a history of psychiatric disorders * recent history of psychotropic and sedative drug use * pregnancy * rejected participants

Keywords: chronic pancreatitis fatigue anxiety depression quality of life